Ed Roy

eroy@illinois.edu

336A Burrill Hall
Office: (217) 333-3375

Mail to: Department of Pathology
College of Medicine, UIUC
506 S. Mathews Ave
Urbana, IL 61801
Video Interview

Ed Roy

Affiliate, Department of Molecular and Integrative Physiology
Professor of Pathology
Professor of Neuroscience

Research Topics

Molecular Immunology

Education

B.A. 1970 Brown University
Ph.D. 1976 University of Massachusetts
Postdoc. 1976-1979 The Rockefeller University

Teaching Interests

Immunotherapy

We are committed to developing immunotherapies for brain tumors that are effective and selective.  We use mice as experimental subjects because much is know about their immune system, and the murine system closely parallels the human immune system.  When properly activated, the immune system has the characteristics of an ideal therapy: potent, precise killing of altered cells.  But there is much to be learned about how to activate, direct, and control the immune response, particularly against tumors within the brain.  We focus mostly on T cell mediated immune responses, and work in close collaboration with the laboratory of David Kranz, a T cell biochemist.

Representative Publications

Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 62 (2013) 359-69.

Chervin, A.S., Stone, Soto, C.M., Engels, B., Schreiber, H., Roy, E.J., Kranz, D.M. Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses. Gene Therapy 20 (2013) 634-44.

Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, MacNeill AL, Roy EJ. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunology Immunotherapy 60 (2011) 1461-72.

Thomas, D. L., Kim, M., Bowerman, N. A., Narayanan, S., Kranz, D. M., Schreiber, H., and Roy, E.J. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. Journal of Immunology, 183 (2009) 1828-1837.

Roy, E.J., Sivaguru, M., Fried, G., Gray, B.D., and Kranz, D.M. Imaging Membrane Intercalating Near Infrared Dyes to Track Multiple Cell Populations. Journal of Immunological Methods, 348 (2009) 18-29.

Complete Publications List